Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-2060 Global Study in Patients with End Stage Renal Disease Receiving Hemodialysis
2024-511055-17-00Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 13
01
Overview
Phase 2, randomised, double-blind trial in Arteriovenous Graft Occlusion comparing MK-2060 with Placebo to MK-2060 (2 arms). Primary endpoint: Time to First Arteriovenous Graft Thrombosis Event. Started Jul 2024; status: completed.
02
Drugs
MK-2060
03
Conditions
Arteriovenous Graft Occlusion
Beyond the preview
Go deeper on 2024-511055-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511055-17-00.